Independent information services
A practical set of guides, comparisons, research summaries, and question frameworks for people evaluating claims about ibogaine treatment for dementia.
Near Beacon 81 does not provide treatment or clinical advice. Our evidence-first dementia and ibogaine overview is built for people affected by dementia, care partners, and anyone who needs a calm way to distinguish an investigational claim from established care.
What these materials are for
Ibogaine is a psychoactive substance associated with significant safety concerns, and it is not an established treatment for dementia. The National Center for Complementary and Integrative Health’s ibogaine overview notes serious risks including heart rhythm problems and death.
That context shapes every information service here: claims are separated from evidence, uncertainty is stated plainly, and safety questions are never treated as a footnote.
Four ways to orient
These are informational offerings, not medical or clinical services. They are designed to make a complicated topic more legible without promising an outcome or directing anyone toward treatment.
Plain-language guides map what is known, what remains speculative, and what a reader should not infer from early or indirect findings. Dementia is a broad term for conditions involving cognitive decline, as described in the National Institute on Aging’s explanation of dementia; this matters when broad claims are made about a single substance.
Question frameworks help readers pause over evidence quality, legal context, medical risk, informed consent, and the difference between a personal story and a reliable clinical conclusion. Our approach and principles explain why independence and plain language guide this work.
Comparisons place ibogaine claims next to what is established, investigational, or unsupported. They are intended to prevent a treatment claim from being mistaken for a standard of care, especially where risk and vulnerability are present.
Research summaries and a working glossary explain study language, evidence limits, and questions to carry into conversations with qualified professionals. Readers weighing practical questions can also review independent context on ibogaine treatment costs in Mexico, while keeping cost separate from evidence of benefit or safety.
A reading discipline
Our summaries are structured to make the limits of the available evidence visible. That includes asking what was studied, in whom, under what conditions, and whether the result speaks to dementia at all.
Independent resource
“A useful brief does not make uncertainty disappear. It makes uncertainty easier to see and discuss.”
Near Beacon 81 is not a clinic, a referral service, or a treatment provider. The goal is to give readers a steadier basis for evaluating statements about ibogaine and dementia, including statements that sound confident but extend beyond the available evidence.
Questions of scope
These answers describe what this resource provides and what it does not provide.
No. Near Beacon 81 is an independent information resource, not a clinic, medical provider, or licensed treatment center. It does not provide treatment, diagnosis, referrals, or medical advice.
No. The guides describe claims and evidence limits. They are designed to support informed questions, not to recommend ibogaine for dementia or any other condition.
Safety is central to interpretation. Ibogaine has known risks, and a claim about potential benefit cannot be evaluated responsibly without considering those risks, the evidence quality, and the difference between investigational work and established care.
Start with the clinical brief
Use the main brief as a starting point for careful evaluation of claims linking ibogaine and dementia.